High throughput AS LNA qPCR method for the detection of a specific mutation in poliovirus vaccine strains
•AS LNA qPCR can accurately identify VP1-E295K containing samples in sPV2 batches.•The developed AS LNA qPCR for E295K mutation is highly sensitive.•LNA probes used are highly specific in targeting known mutations.•AS LNA qPCR is likely applicable to other vaccine strains, serotypes, and mutations....
Gespeichert in:
Veröffentlicht in: | Vaccine 2024-04, Vol.42 (9), p.2475-2484 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2484 |
---|---|
container_issue | 9 |
container_start_page | 2475 |
container_title | Vaccine |
container_volume | 42 |
creator | Opmeer, Lizet Gazzoli, Isabella Ballmann, Mónika Willemsen, Marieke Voshol, Gerben P. Grudniewska-Lawton, Magda Havenga, Menzo Yallop, Christopher Hamidi, Ahd Gillissen, Gert Bakker, Wilfried A.M. |
description | •AS LNA qPCR can accurately identify VP1-E295K containing samples in sPV2 batches.•The developed AS LNA qPCR for E295K mutation is highly sensitive.•LNA probes used are highly specific in targeting known mutations.•AS LNA qPCR is likely applicable to other vaccine strains, serotypes, and mutations.
Sabin Inactivated Poliovirus Vaccine (sIPV) has become one of the preferred vaccination options for the last step in the Poliovirus eradication program. Sequencing of poliovirus samples is needed during the manufacturing of poliovirus vaccines to assure the safety and immunogenicity of these vaccines. Next-generation sequencing analysis is the current costly and time-consuming gold standard for monitoring the manufacturing processes. We developed a low-cost and quick, highly sensitive, and allele-specific locked nucleic acid-probe-based reverse transcription quantitative PCR alternative that can accurately detect mutations in poliovirus vaccine samples during process development, scaling up, and release. Using the frequently in vitro occurring and viral replication-impacting VP1-E295K mutation as a showcase, we show that this technology can accurately detect E295K mutations in poliovirus 2 samples to similar levels as NGS. The qPCR technology was developed employing a synthetic dsDNA fragment-based standard curve containing mixes of E295K-WT (wildtype) and Mut (mutant) synthetic dsDNA fragments ranging from 1 × 107 copies/µL to 1 × 102 copies/µL to achieve a linear correlation with R2 > 0.999, and PCR efficiencies of 95–105 %. Individual standard concentration levels achieved accuracies of ≥92 % (average 96 %) and precisions of ≤17 % (average 3.3 %) RSD. Specificity of locked nucleic acid (LNA)-probes was confirmed in the presence and absence of co-mutations in the probe-binding region. Application of the developed assay to Sabin Poliovirus type 2 production run samples, illustrated a linear relationship with an R2 of 0.994, and an average accuracy of 97.2 % of the variant (allele)-specific AS LNA qPCR result, compared to NGS. The assay showed good sensitivity for poliovirus samples, containing E295K mutation levels between 0 % and 95 % (quantification range).
In conclusion, the developed AS LNA qPCR presents a valuable low-cost, and fast tool, suitable for the process development and quality control of polio vaccines. |
doi_str_mv | 10.1016/j.vaccine.2024.01.103 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11007389</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X24001300</els_id><sourcerecordid>3153183633</sourcerecordid><originalsourceid>FETCH-LOGICAL-c477t-664fb8cab629be8d9aee793df346d526fb79c37cea417d48fab38790ee0950af3</originalsourceid><addsrcrecordid>eNqFUV2L1DAUDaK44-pPUAK--NLxpmmT9kmGYXWFQcUP8C2k6c00Q9t0k3bAf2_GHdePl4VA4NyTc0_OIeQ5gzUDJl4f1kdtjBtxnUNerIElmD8gK1ZJnuUlqx6SFeSiyAoG3y_IkxgPAFByVj8mF7wqgQsBK-Ku3b6jcxf8su-mZaabL3T3YUNvPm0_0wHnzrfU-pAYSFuc0czOj9Rbqmmc0DjrDB2WWf-C3Ugn3zt_dGGJ9OyPxjloN8an5JHVfcRn5_uSfHt79XV7ne0-vnu_3ewyU0g5Z0IUtqmMbkReN1i1tUaUNW8tL0Rb5sI2sjZcGtQFk21RWd3wStaACHUJ2vJL8uZWd1qaAVuDY9rfqym4QYcfymun_p2MrlN7f1SMAUhe1Unh1Vkh-JsF46wGFw32vR7RL1FxlmKsuOD8Xmpey1xCOkWivvyPevBLGFMUigNnogLgeWKVtywTfIwB7Z1xBupUvDqoc7DqVLwCluCTkRd___ru1e-m_8SCKfujw6CicTgabF1IrarWu3tW_AS5zMKE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3031680032</pqid></control><display><type>article</type><title>High throughput AS LNA qPCR method for the detection of a specific mutation in poliovirus vaccine strains</title><source>ScienceDirect Journals (5 years ago - present)</source><source>ProQuest Central UK/Ireland</source><creator>Opmeer, Lizet ; Gazzoli, Isabella ; Ballmann, Mónika ; Willemsen, Marieke ; Voshol, Gerben P. ; Grudniewska-Lawton, Magda ; Havenga, Menzo ; Yallop, Christopher ; Hamidi, Ahd ; Gillissen, Gert ; Bakker, Wilfried A.M.</creator><creatorcontrib>Opmeer, Lizet ; Gazzoli, Isabella ; Ballmann, Mónika ; Willemsen, Marieke ; Voshol, Gerben P. ; Grudniewska-Lawton, Magda ; Havenga, Menzo ; Yallop, Christopher ; Hamidi, Ahd ; Gillissen, Gert ; Bakker, Wilfried A.M.</creatorcontrib><description>•AS LNA qPCR can accurately identify VP1-E295K containing samples in sPV2 batches.•The developed AS LNA qPCR for E295K mutation is highly sensitive.•LNA probes used are highly specific in targeting known mutations.•AS LNA qPCR is likely applicable to other vaccine strains, serotypes, and mutations.
Sabin Inactivated Poliovirus Vaccine (sIPV) has become one of the preferred vaccination options for the last step in the Poliovirus eradication program. Sequencing of poliovirus samples is needed during the manufacturing of poliovirus vaccines to assure the safety and immunogenicity of these vaccines. Next-generation sequencing analysis is the current costly and time-consuming gold standard for monitoring the manufacturing processes. We developed a low-cost and quick, highly sensitive, and allele-specific locked nucleic acid-probe-based reverse transcription quantitative PCR alternative that can accurately detect mutations in poliovirus vaccine samples during process development, scaling up, and release. Using the frequently in vitro occurring and viral replication-impacting VP1-E295K mutation as a showcase, we show that this technology can accurately detect E295K mutations in poliovirus 2 samples to similar levels as NGS. The qPCR technology was developed employing a synthetic dsDNA fragment-based standard curve containing mixes of E295K-WT (wildtype) and Mut (mutant) synthetic dsDNA fragments ranging from 1 × 107 copies/µL to 1 × 102 copies/µL to achieve a linear correlation with R2 > 0.999, and PCR efficiencies of 95–105 %. Individual standard concentration levels achieved accuracies of ≥92 % (average 96 %) and precisions of ≤17 % (average 3.3 %) RSD. Specificity of locked nucleic acid (LNA)-probes was confirmed in the presence and absence of co-mutations in the probe-binding region. Application of the developed assay to Sabin Poliovirus type 2 production run samples, illustrated a linear relationship with an R2 of 0.994, and an average accuracy of 97.2 % of the variant (allele)-specific AS LNA qPCR result, compared to NGS. The assay showed good sensitivity for poliovirus samples, containing E295K mutation levels between 0 % and 95 % (quantification range).
In conclusion, the developed AS LNA qPCR presents a valuable low-cost, and fast tool, suitable for the process development and quality control of polio vaccines.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2024.01.103</identifier><identifier>PMID: 38503660</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Acids ; Alleles ; AS LNA qPCR ; Cost analysis ; DNA ; Enterovirus C ; Immunogenicity ; Invoices ; Low cost ; Manufacturing ; Manufacturing industry ; mutants ; Mutation ; Mutations ; Next-generation sequencing ; NGS ; Nucleic acids ; Poliomyelitis ; Poliovirus ; Polymerase chain reaction ; qPCR ; Quality control ; reverse transcriptase polymerase chain reaction ; Reverse transcription ; Sabin Poliovirus 2 ; Sarcoma ; Sequence analysis ; sIPV ; vaccination ; Vaccine ; Vaccines ; VP1 protein ; VP1-E295K</subject><ispartof>Vaccine, 2024-04, Vol.42 (9), p.2475-2484</ispartof><rights>2024 The Author(s)</rights><rights>Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.</rights><rights>2024. The Author(s)</rights><rights>2024 The Author(s) 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c477t-664fb8cab629be8d9aee793df346d526fb79c37cea417d48fab38790ee0950af3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/3031680032?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,778,782,883,3539,27907,27908,45978,64366,64368,64370,72220</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38503660$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Opmeer, Lizet</creatorcontrib><creatorcontrib>Gazzoli, Isabella</creatorcontrib><creatorcontrib>Ballmann, Mónika</creatorcontrib><creatorcontrib>Willemsen, Marieke</creatorcontrib><creatorcontrib>Voshol, Gerben P.</creatorcontrib><creatorcontrib>Grudniewska-Lawton, Magda</creatorcontrib><creatorcontrib>Havenga, Menzo</creatorcontrib><creatorcontrib>Yallop, Christopher</creatorcontrib><creatorcontrib>Hamidi, Ahd</creatorcontrib><creatorcontrib>Gillissen, Gert</creatorcontrib><creatorcontrib>Bakker, Wilfried A.M.</creatorcontrib><title>High throughput AS LNA qPCR method for the detection of a specific mutation in poliovirus vaccine strains</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>•AS LNA qPCR can accurately identify VP1-E295K containing samples in sPV2 batches.•The developed AS LNA qPCR for E295K mutation is highly sensitive.•LNA probes used are highly specific in targeting known mutations.•AS LNA qPCR is likely applicable to other vaccine strains, serotypes, and mutations.
Sabin Inactivated Poliovirus Vaccine (sIPV) has become one of the preferred vaccination options for the last step in the Poliovirus eradication program. Sequencing of poliovirus samples is needed during the manufacturing of poliovirus vaccines to assure the safety and immunogenicity of these vaccines. Next-generation sequencing analysis is the current costly and time-consuming gold standard for monitoring the manufacturing processes. We developed a low-cost and quick, highly sensitive, and allele-specific locked nucleic acid-probe-based reverse transcription quantitative PCR alternative that can accurately detect mutations in poliovirus vaccine samples during process development, scaling up, and release. Using the frequently in vitro occurring and viral replication-impacting VP1-E295K mutation as a showcase, we show that this technology can accurately detect E295K mutations in poliovirus 2 samples to similar levels as NGS. The qPCR technology was developed employing a synthetic dsDNA fragment-based standard curve containing mixes of E295K-WT (wildtype) and Mut (mutant) synthetic dsDNA fragments ranging from 1 × 107 copies/µL to 1 × 102 copies/µL to achieve a linear correlation with R2 > 0.999, and PCR efficiencies of 95–105 %. Individual standard concentration levels achieved accuracies of ≥92 % (average 96 %) and precisions of ≤17 % (average 3.3 %) RSD. Specificity of locked nucleic acid (LNA)-probes was confirmed in the presence and absence of co-mutations in the probe-binding region. Application of the developed assay to Sabin Poliovirus type 2 production run samples, illustrated a linear relationship with an R2 of 0.994, and an average accuracy of 97.2 % of the variant (allele)-specific AS LNA qPCR result, compared to NGS. The assay showed good sensitivity for poliovirus samples, containing E295K mutation levels between 0 % and 95 % (quantification range).
In conclusion, the developed AS LNA qPCR presents a valuable low-cost, and fast tool, suitable for the process development and quality control of polio vaccines.</description><subject>Acids</subject><subject>Alleles</subject><subject>AS LNA qPCR</subject><subject>Cost analysis</subject><subject>DNA</subject><subject>Enterovirus C</subject><subject>Immunogenicity</subject><subject>Invoices</subject><subject>Low cost</subject><subject>Manufacturing</subject><subject>Manufacturing industry</subject><subject>mutants</subject><subject>Mutation</subject><subject>Mutations</subject><subject>Next-generation sequencing</subject><subject>NGS</subject><subject>Nucleic acids</subject><subject>Poliomyelitis</subject><subject>Poliovirus</subject><subject>Polymerase chain reaction</subject><subject>qPCR</subject><subject>Quality control</subject><subject>reverse transcriptase polymerase chain reaction</subject><subject>Reverse transcription</subject><subject>Sabin Poliovirus 2</subject><subject>Sarcoma</subject><subject>Sequence analysis</subject><subject>sIPV</subject><subject>vaccination</subject><subject>Vaccine</subject><subject>Vaccines</subject><subject>VP1 protein</subject><subject>VP1-E295K</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFUV2L1DAUDaK44-pPUAK--NLxpmmT9kmGYXWFQcUP8C2k6c00Q9t0k3bAf2_GHdePl4VA4NyTc0_OIeQ5gzUDJl4f1kdtjBtxnUNerIElmD8gK1ZJnuUlqx6SFeSiyAoG3y_IkxgPAFByVj8mF7wqgQsBK-Ku3b6jcxf8su-mZaabL3T3YUNvPm0_0wHnzrfU-pAYSFuc0czOj9Rbqmmc0DjrDB2WWf-C3Ugn3zt_dGGJ9OyPxjloN8an5JHVfcRn5_uSfHt79XV7ne0-vnu_3ewyU0g5Z0IUtqmMbkReN1i1tUaUNW8tL0Rb5sI2sjZcGtQFk21RWd3wStaACHUJ2vJL8uZWd1qaAVuDY9rfqym4QYcfymun_p2MrlN7f1SMAUhe1Unh1Vkh-JsF46wGFw32vR7RL1FxlmKsuOD8Xmpey1xCOkWivvyPevBLGFMUigNnogLgeWKVtywTfIwB7Z1xBupUvDqoc7DqVLwCluCTkRd___ru1e-m_8SCKfujw6CicTgabF1IrarWu3tW_AS5zMKE</recordid><startdate>20240402</startdate><enddate>20240402</enddate><creator>Opmeer, Lizet</creator><creator>Gazzoli, Isabella</creator><creator>Ballmann, Mónika</creator><creator>Willemsen, Marieke</creator><creator>Voshol, Gerben P.</creator><creator>Grudniewska-Lawton, Magda</creator><creator>Havenga, Menzo</creator><creator>Yallop, Christopher</creator><creator>Hamidi, Ahd</creator><creator>Gillissen, Gert</creator><creator>Bakker, Wilfried A.M.</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><general>Elsevier Science</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope><scope>5PM</scope></search><sort><creationdate>20240402</creationdate><title>High throughput AS LNA qPCR method for the detection of a specific mutation in poliovirus vaccine strains</title><author>Opmeer, Lizet ; Gazzoli, Isabella ; Ballmann, Mónika ; Willemsen, Marieke ; Voshol, Gerben P. ; Grudniewska-Lawton, Magda ; Havenga, Menzo ; Yallop, Christopher ; Hamidi, Ahd ; Gillissen, Gert ; Bakker, Wilfried A.M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c477t-664fb8cab629be8d9aee793df346d526fb79c37cea417d48fab38790ee0950af3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Acids</topic><topic>Alleles</topic><topic>AS LNA qPCR</topic><topic>Cost analysis</topic><topic>DNA</topic><topic>Enterovirus C</topic><topic>Immunogenicity</topic><topic>Invoices</topic><topic>Low cost</topic><topic>Manufacturing</topic><topic>Manufacturing industry</topic><topic>mutants</topic><topic>Mutation</topic><topic>Mutations</topic><topic>Next-generation sequencing</topic><topic>NGS</topic><topic>Nucleic acids</topic><topic>Poliomyelitis</topic><topic>Poliovirus</topic><topic>Polymerase chain reaction</topic><topic>qPCR</topic><topic>Quality control</topic><topic>reverse transcriptase polymerase chain reaction</topic><topic>Reverse transcription</topic><topic>Sabin Poliovirus 2</topic><topic>Sarcoma</topic><topic>Sequence analysis</topic><topic>sIPV</topic><topic>vaccination</topic><topic>Vaccine</topic><topic>Vaccines</topic><topic>VP1 protein</topic><topic>VP1-E295K</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Opmeer, Lizet</creatorcontrib><creatorcontrib>Gazzoli, Isabella</creatorcontrib><creatorcontrib>Ballmann, Mónika</creatorcontrib><creatorcontrib>Willemsen, Marieke</creatorcontrib><creatorcontrib>Voshol, Gerben P.</creatorcontrib><creatorcontrib>Grudniewska-Lawton, Magda</creatorcontrib><creatorcontrib>Havenga, Menzo</creatorcontrib><creatorcontrib>Yallop, Christopher</creatorcontrib><creatorcontrib>Hamidi, Ahd</creatorcontrib><creatorcontrib>Gillissen, Gert</creatorcontrib><creatorcontrib>Bakker, Wilfried A.M.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Opmeer, Lizet</au><au>Gazzoli, Isabella</au><au>Ballmann, Mónika</au><au>Willemsen, Marieke</au><au>Voshol, Gerben P.</au><au>Grudniewska-Lawton, Magda</au><au>Havenga, Menzo</au><au>Yallop, Christopher</au><au>Hamidi, Ahd</au><au>Gillissen, Gert</au><au>Bakker, Wilfried A.M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High throughput AS LNA qPCR method for the detection of a specific mutation in poliovirus vaccine strains</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2024-04-02</date><risdate>2024</risdate><volume>42</volume><issue>9</issue><spage>2475</spage><epage>2484</epage><pages>2475-2484</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>•AS LNA qPCR can accurately identify VP1-E295K containing samples in sPV2 batches.•The developed AS LNA qPCR for E295K mutation is highly sensitive.•LNA probes used are highly specific in targeting known mutations.•AS LNA qPCR is likely applicable to other vaccine strains, serotypes, and mutations.
Sabin Inactivated Poliovirus Vaccine (sIPV) has become one of the preferred vaccination options for the last step in the Poliovirus eradication program. Sequencing of poliovirus samples is needed during the manufacturing of poliovirus vaccines to assure the safety and immunogenicity of these vaccines. Next-generation sequencing analysis is the current costly and time-consuming gold standard for monitoring the manufacturing processes. We developed a low-cost and quick, highly sensitive, and allele-specific locked nucleic acid-probe-based reverse transcription quantitative PCR alternative that can accurately detect mutations in poliovirus vaccine samples during process development, scaling up, and release. Using the frequently in vitro occurring and viral replication-impacting VP1-E295K mutation as a showcase, we show that this technology can accurately detect E295K mutations in poliovirus 2 samples to similar levels as NGS. The qPCR technology was developed employing a synthetic dsDNA fragment-based standard curve containing mixes of E295K-WT (wildtype) and Mut (mutant) synthetic dsDNA fragments ranging from 1 × 107 copies/µL to 1 × 102 copies/µL to achieve a linear correlation with R2 > 0.999, and PCR efficiencies of 95–105 %. Individual standard concentration levels achieved accuracies of ≥92 % (average 96 %) and precisions of ≤17 % (average 3.3 %) RSD. Specificity of locked nucleic acid (LNA)-probes was confirmed in the presence and absence of co-mutations in the probe-binding region. Application of the developed assay to Sabin Poliovirus type 2 production run samples, illustrated a linear relationship with an R2 of 0.994, and an average accuracy of 97.2 % of the variant (allele)-specific AS LNA qPCR result, compared to NGS. The assay showed good sensitivity for poliovirus samples, containing E295K mutation levels between 0 % and 95 % (quantification range).
In conclusion, the developed AS LNA qPCR presents a valuable low-cost, and fast tool, suitable for the process development and quality control of polio vaccines.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>38503660</pmid><doi>10.1016/j.vaccine.2024.01.103</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0264-410X |
ispartof | Vaccine, 2024-04, Vol.42 (9), p.2475-2484 |
issn | 0264-410X 1873-2518 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11007389 |
source | ScienceDirect Journals (5 years ago - present); ProQuest Central UK/Ireland |
subjects | Acids Alleles AS LNA qPCR Cost analysis DNA Enterovirus C Immunogenicity Invoices Low cost Manufacturing Manufacturing industry mutants Mutation Mutations Next-generation sequencing NGS Nucleic acids Poliomyelitis Poliovirus Polymerase chain reaction qPCR Quality control reverse transcriptase polymerase chain reaction Reverse transcription Sabin Poliovirus 2 Sarcoma Sequence analysis sIPV vaccination Vaccine Vaccines VP1 protein VP1-E295K |
title | High throughput AS LNA qPCR method for the detection of a specific mutation in poliovirus vaccine strains |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T17%3A05%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High%20throughput%20AS%20LNA%20qPCR%20method%20for%20the%20detection%20of%20a%20specific%20mutation%20in%20poliovirus%20vaccine%20strains&rft.jtitle=Vaccine&rft.au=Opmeer,%20Lizet&rft.date=2024-04-02&rft.volume=42&rft.issue=9&rft.spage=2475&rft.epage=2484&rft.pages=2475-2484&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2024.01.103&rft_dat=%3Cproquest_pubme%3E3153183633%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3031680032&rft_id=info:pmid/38503660&rft_els_id=S0264410X24001300&rfr_iscdi=true |